2,205 results match your criteria Cancer gene therapy[Journal]


HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate.

Cancer Gene Ther 2020 Jul 10. Epub 2020 Jul 10.

Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Acute myeloid leukemia (AML) is a poor prognosis hematopoietic malignance characterized by abnormal proliferation and differentiation of hematopoietic stem cells (HSCs). Although advances in treatment have greatly improved survival rates in young patients, in the elderly population, ~70% of patients present poor prognosis. A pan-cancer analysis on the TCGA cohort showed that AML has the second higher HUWE1 expression in tumor samples among all cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0198-3DOI Listing

Modeling oncolytic virus dynamics in the tumor microenvironment using zebrafish.

Cancer Gene Ther 2020 Jul 10. Epub 2020 Jul 10.

Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

We have adapted a zebrafish (Danio rerio) tumor xenograft model for use in the study of oncolytic virotherapy. Following implantation of mammalian cancer cells into the perivitelline space of developing zebrafish embryos, both local and intravenous oncolytic virus treatments produce a tumor-specific infection with measurable antitumor effects. Tumor cells are injected at 48 h post fertilization, with oncolytic virus treatment then being administered 24 h later to allow for an initial period of tumor development and angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0194-7DOI Listing

Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy.

Cancer Gene Ther 2020 Jul 7. Epub 2020 Jul 7.

Department of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Adoptive cell therapy (ACT) using tumor-specific tumor-infiltrating lymphocytes (TILs) has demonstrated success in patients where tumor-antigen specific TILs can be harvested from the tumor, expanded, and re-infused in combination with a preparatory regimen and IL2. One major issue for non-immunogenic tumors has been that the isolated TILs lack tumor specificity and thus possess limited in vivo therapeutic function. An oncolytic virus (OV) mediates an immunogenic cell death for cancer cells, leading to elicitation and dramatic enhancement of tumor-specific TILs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0189-4DOI Listing

Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt/β-catenin signaling pathway.

Cancer Gene Ther 2020 Jul 7. Epub 2020 Jul 7.

Department of Obstetrics and Gynecology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, 200011, Shanghai, P.R. China.

Cisplatin (DDP)-based strategies are the first-line treatment for cancers; however, resistance to DDP remains a major obstacle to cancer treatment. The current study set out to investigate the effects of microRNA-181c (miR-181c) on the resistance of ovarian cancer cells to DDP. Ovarian cancer-associated miRs as well as the target messenger RNAs were screened using microarray-based analysis followed by determining the expression patterns of miR-181c and mesoderm-specific transcript (MEST) in ovarian cancer tissues with RT-qPCR and Western blot analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0195-6DOI Listing

An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.

Cancer Gene Ther 2020 Jul 7. Epub 2020 Jul 7.

Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Tumor organoids recapitulate pathological properties and would serve as an excellent ex vivo model for drug discovery. Here, we performed an unbiased drug screening on drivers-defined tumor organoids from mouse endometrial cancer, the most prevalent gynecological malignancy in human, with a small molecule library targeting epigenetic factors. Among them, menin-MLL inhibitors MI-136 and MI-463 scored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0190-yDOI Listing

MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma.

Cancer Gene Ther 2020 Jul 3. Epub 2020 Jul 3.

Department of Oncology, The General Hospital of Western Theater Command PLA, Chengdu, 610083, Sichuan Province, China.

Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the first-line systemic therapy for advanced hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) have been reported to play critical roles in the initiation, progression, and drug resistance of HCC. In this study, we aimed to identify sorafenib-induced miRNAs and demonstrate their regulatory roles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0191-xDOI Listing

Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.

Cancer Gene Ther 2020 Jul 1. Epub 2020 Jul 1.

Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Oncolytic viruses are designed to replicate in and kill cancer cells, and have shown tremendous promise in preclinical and clinical studies. Indeed, several oncolytic viruses are available to patients in a number of different countries around the world. However, most oncolytic viruses show a poor ability to spread throughout the tumor mass, frequently leading to only a partial response and regrowth of the tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0192-9DOI Listing

Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.

Cancer Gene Ther 2020 Jun 29. Epub 2020 Jun 29.

Department of Surgery and Cancer, Ovarian Cancer Action Research Centre, Imperial College London, London, W12 0NN, UK.

OPCML is a highly conserved glycosyl phosphatidylinositol (GPI)-anchored protein belonging to the IgLON family of cell adhesion molecules. OPCML functions as a tumor suppressor and is silenced in over 80% of ovarian cancers by loss of heterozygosity and by epigenetic mechanisms. OPCML inactivation is also observed in many other cancers suggesting a conservation of tumor suppressor function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0187-6DOI Listing

LIPG: an inflammation and cancer modulator.

Cancer Gene Ther 2020 Jun 23. Epub 2020 Jun 23.

Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, PR China.

Endothelial lipase (LIPG/EL) performs fundamental and vital roles in the human body, including cell composition, cytokine expression, and energy provision. Since LIPG predominantly functions as a phospholipase as well as presents low levels of triglyceride lipase activity, it plays an essential role in lipoprotein metabolism, and involves in the metabolic syndromes such as inflammatory response and atherosclerosis. Cytokines significantly affect LIPG expression in endothelial cells in many diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0188-5DOI Listing

The tumor-suppressive role of microRNA-873 in nasopharyngeal carcinoma correlates with downregulation of ZIC2 and inhibition of AKT signaling pathway.

Cancer Gene Ther 2020 Jun 18. Epub 2020 Jun 18.

Department of E.N.T., Linyi People's Hospital, 276000, Linyi, P.R. China.

Cancer stem cells (CSCs) are responsible for tumor initiation, relapse, and metastasis. Thus, residual CSCs after chemotherapy may result in poor prognosis for nasopharyngeal carcinoma (NPC). Emerging evidence suggests that differentially expressed microRNAs (miRNAs) regulate genes that carry out important functions in CSCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0185-8DOI Listing

Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.

Cancer Gene Ther 2020 Jun 12. Epub 2020 Jun 12.

Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Apatinib, a selective vascular endothelial growth factor receptor 2-tyrosine kinase inhibitor, has demonstrated activity against a wide range of solid tumors, including advanced hepatocellular carcinoma (HCC). Preclinical and preliminary clinical results have confirmed the synergistic antitumor effects of apatinib in combination with anti-programmed death-1 (PD-1) blockade. However, the immunologic mechanism of this combination therapy remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0186-7DOI Listing
June 2020
2.416 Impact Factor

Retraction Note: MALAT2-activated long noncoding RNA indicates a biomarker of poor prognosis in gastric cancer.

Cancer Gene Ther 2020 Jun;27(6):514

Division of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0177-8DOI Listing

AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses.

Cancer Gene Ther 2020 May 27. Epub 2020 May 27.

Cellular Biotechnology Unit, Instituto de Salud Carlos III, 28220, Madrid, Spain.

There is increasing evidence about the use of oncolytic adenoviruses (Ads) as promising immunotherapy agents. We have previously demonstrated the clinical efficiency of mesenchymal stem cells (MSCs) infected with oncolytic Ads as an antitumoral immunotherapy (called Celyvir) in human and canine patients, using ICOVIR-5 or ICOCAV17 as human and canine oncolytic Ads, respectively. Considering the better clinical outcomes of canine patients, in this study we searched for differences in cellular responses of human and canine MSCs to Ad infection that may help understand the mechanisms leading to higher antitumor immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0184-9DOI Listing
May 2020
2.416 Impact Factor

Revisiting the role of CD4 T cells in cancer immunotherapy-new insights into old paradigms.

Cancer Gene Ther 2020 May 27. Epub 2020 May 27.

Singapore Immunology Network, Agency for Science, Technology, and Research (A*STAR), Singapore, 138648, Singapore.

Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of care across a growing number of cancer indications. While the majority of cancer immunotherapies focus on harnessing the anti-tumour CD8 cytotoxic T cell response, the potential role of CD4 'helper' T cells has largely remained in the background. In this review, we give an overview of the multifaceted role of CD4 T cells in the anti-tumour immune response, with an emphasis on recent evidence that CD4 T cells play a bigger role than previously thought. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0183-xDOI Listing

Interplay between MTOR and GPX4 signaling modulates autophagy-dependent ferroptotic cancer cell death.

Cancer Gene Ther 2020 May 27. Epub 2020 May 27.

The Third Affiliated Hospital, Guangzhou Medical University, 510510, Guangzhou, Guangdong, China.

Ferroptosis has become a topic of rapidly growing interest in recent years, and has possible therapy implications in cancer therapy. Although excessive autophagy may contribute to ferroptosis, its underlying molecular mechanism remains largely unknown. Here, we provide novel evidence that the interplay between the signals of mechanistic target of rapamycin kinase (MTOR) and glutathione peroxidase 4 (GPX4) modulates autophagy-dependent ferroptosis in human pancreatic cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0182-yDOI Listing

RHPN1-AS1 promotes cell proliferation and migration via miR-665/Akt3 in ovarian cancer.

Cancer Gene Ther 2020 May 27. Epub 2020 May 27.

Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Xi' an Jiaotong University, 710061, Xi' an, China.

Recent efforts have revealed that long non-coding RNAs exert crucial roles in cancer initiation and progression. RHPN1-AS1 is a 2030 bp transcript from human chromosome 8q24, and involved in tumorigenesis in uveal melanoma and non-small cell lung cancer, but it remains unknown in ovarian cancer. This study focused on the role of RHPN1-AS1 in ovarian cancer and found that RHPN1-AS1 was up-regulated in ovarian cancer tissues and cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0180-0DOI Listing

LincRNA-ROR is activated by H3K27 acetylation and induces EMT in retinoblastoma by acting as a sponge of miR-32 to activate the Notch signaling pathway.

Cancer Gene Ther 2020 May 22. Epub 2020 May 22.

Department of Obstetrics and Gynecology, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, China.

Recent studies have suggested that lincRNA-ROR is involved in the tumorigenesis of different types of cancers. However, the role of lincRNA-ROR in retinoblastoma has not been determined. We investigated lincRNA-ROR levels in 58 retinoblastoma and adjacent non-tumor tissues by quantitative reverse transcription PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0181-zDOI Listing

Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.

Cancer Gene Ther 2020 May 18. Epub 2020 May 18.

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Cancer immunotherapy emerged as a novel therapeutic option that employs enhanced or amended native immune system to create a robust response against malignant cells. The systemic therapies with immune-stimulating cytokines have resulted in substantial dose-limiting toxicities. Targeted cytokine immunotherapy is being explored to overcome the heterogeneity of malignant cells and tumor cell defense with a remarkable reduction of systemic side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0179-6DOI Listing
May 2020
2.416 Impact Factor

Improvement of muscular atrophy by AAV-SaCas9-mediated myostatin gene editing in aged mice.

Cancer Gene Ther 2020 May 13. Epub 2020 May 13.

College of Animal Sciences and Veterinary Medicine, Henan Agricultural University, 450002, Zhengzhou, Henan Province, People's Republic of China.

Muscle mass and area usually decrease with age, and this phenomenon is known as sarcopenia. This age-related atrophy correlates with insufficient levels of muscle cells differentiate and proliferate regulated by the TGF-β signaling pathway and the expression of E3s ubiquitin-protein ligase by the aged. Sarcopenia makes a huge impact on the aging society, because it has the characteristic of high incidence, extensive adverse effects and disease aggravation gradually. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0178-7DOI Listing

UNC5B mediates G2/M phase arrest of bladder cancer cells by binding to CDC14A and P53.

Cancer Gene Ther 2020 May 6. Epub 2020 May 6.

Department of Urology, The First Hospital of China Medical University, Shenyang, 110001, China.

UNC5B is a known tumor suppressor gene in a variety of cancers. As a transmembrane protein, UNC5B also induces apoptosis in a P53-dependent manner. In this study, we demonstrate that UNC5B inhibits proliferation through G2/M phase arrest by mass spectrometry and bioinformatics analysis in bladder cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0175-xDOI Listing

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Cancer Gene Ther 2020 May 1. Epub 2020 May 1.

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Multiple myeloma (MM) is a plasma cell malignancy that is characterized by immune dysregulation. MM is commonly treated with immunomodulating agents, but still remains incurable. Herein, we proposed and evaluated immunostimulatory Lokon oncolytic adenoviruses (LOAd) for MM treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0176-9DOI Listing

TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.

Cancer Gene Ther 2020 Apr 28. Epub 2020 Apr 28.

Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.

Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, we review checkpoint inhibitor signal pathways, resistance and sensitivity mechanisms, as well as response rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0174-yDOI Listing

Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.

Cancer Gene Ther 2020 Apr 20. Epub 2020 Apr 20.

Anhui Medical University, Hefei, 230032, Anhui, PR China.

LIGHT, also known as tumor-necrosis factor (TNF) superfamily member 14 (TNFSF14), is predominantly expressed on activated immune cells and some tumor cells. LIGHT is a pivotal regulator both for recruiting and activating immune cells in the tumor lesions. In this study, we armed human telomerase reverse transcriptase (TERT) promoter controlled oncolytic adenovirus with LIGHT to generate rAd. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0173-zDOI Listing
April 2020
2.416 Impact Factor

In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.

Cancer Gene Ther 2020 Mar 31. Epub 2020 Mar 31.

Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL, USA.

The tumor stroma acts as a barrier that limits the efficacy of systemically administered oncolytic viruses (OV). We previously demonstrated that stromal-selective, retargeted oncolytic measles viruses (MVs) delay in vivo tumor progression. To further characterize the contribution of stromal targeting to MV's overall in vivo efficacy in an experimental cancer model, a dual targeted oncolytic measles virus (MV-CD46-muPA) able to simultaneously infect murine stromal (via murine uPAR) and human cancer (via CD46) cells was developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0171-1DOI Listing

MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis.

Cancer Gene Ther 2020 Mar 23. Epub 2020 Mar 23.

Iranian Red Crescent Society, Tehran, Iran.

Inflammation, among environmental risk factors, is one of the most important contributors to colorectal cancer (CRC) development. In this way, studies revealed that the incidence of CRC in inflammatory bowel disease patients is up to 60% higher than the general population. MicroRNAs (miRNAs), small noncoding RNA molecules, have attracted excessive attention due to their fundamental role in various aspects of cellular biology, such as inflammation by binding to the 3'-untranslated regions (3'-UTR) of pro and anti-inflammatory genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0172-0DOI Listing
March 2020
2.416 Impact Factor

Transcription factors in ferroptotic cell death.

Cancer Gene Ther 2020 Mar 3. Epub 2020 Mar 3.

Department of Surgery, UT Southwestern Medical Center, Dallas, TX, 75390, USA.

Ferroptosis, a form of regulated cell death, is characterized by an excessive degree of iron accumulation and lipid peroxidation. Although it was originally identified only in cells expressing a mutant RAS oncogene, ferroptosis has also been found in normal cells following treatment by small molecules (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0170-2DOI Listing

Reviewer Recognition.

Authors:
Georgios Giamas

Cancer Gene Ther 2020 Apr;27(3-4):264

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0168-9DOI Listing

Cancer Gene Therapy: vision and strategy for the new decade.

Authors:
Georgios Giamas

Cancer Gene Ther 2020 Apr;27(3-4):115

Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, BN1 9QG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0169-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170802PMC

Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.

Cancer Gene Ther 2020 Feb 7. Epub 2020 Feb 7.

Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.

Surgical resection is the only cure for neuroendocrine tumors (NETs). However, widespread metastases have already occured by the time of initial diagnosis in many cases making complete surgical removal impossible. We developed a recombinant heavy-chain receptor binding domain (rHCR) of botulinum neurotoxin type A that can specifically target synaptic vesicle 2 (SV2), a surface receptor abundantly expressed in multiple neuroendocrine tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0167-xDOI Listing
February 2020

Editorial expression of concern: Cdc6 expression is induced by HPV16 E6 and E7 oncogenes and represses E-cadherin expression.

Cancer Gene Ther 2020 May;27(5):394

Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0165-zDOI Listing

PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.

Cancer Gene Ther 2020 Jan 28. Epub 2020 Jan 28.

Division of Hematology and Medical Oncology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.

Phosphoinositide kinases (PIKs) are a group of lipid kinases that are important upstream activators of various signaling pathways that drive oncogenesis. Hyperactivation of the PI3K/AKT/mTOR pathways-either via mutations or genomic amplification-confers key oncogenic activity, essential for the development and progression of several solid tumors. Alterations in the PIK3CA gene are associated with poor prognosis of solid malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0164-0DOI Listing
January 2020

Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma.

Cancer Gene Ther 2020 Jan 28. Epub 2020 Jan 28.

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.

Despite the fact that a few novel agents improve the outcome of patients, MM remains incurable. Hence, developing a novel treatment strategy may prove to be promising for the clinical management of MM. Noncoding small RNAs, a cluster of RNAs that do not encode functional proteins, have been underlined that play a pivotal role in the pathogenesis of MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0161-3DOI Listing
January 2020
2.416 Impact Factor

Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.

Cancer Gene Ther 2020 Jan 28. Epub 2020 Jan 28.

Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.

Epidermal growth factor receptor (EGFR) gene amplification and mutation occurs most frequently in glioblastoma (GBM). However, EGFR-tyrosine kinase inhibitors (TKIs), including gefitinib, have not yet shown clear clinical benefit and the underlying mechanisms remain largely unexplored. We previously demonstrated that LRIG2 plays a protumorigenic role and functions as a modulator of multiple oncogenic receptor tyrosine kinases (RTKs) in GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0163-1DOI Listing
January 2020

Prognostic role of minichromosome maintenance family in multiple myeloma.

Cancer Gene Ther 2020 Jan 21. Epub 2020 Jan 21.

Department of Operations and Information Management, China-Japan Friendship Hospital, 100029, Beijing, China.

Multiple myeloma (MM) is a plasma cell malignancy. The minichromosome maintenance (MCM) family involve in DNA replication and is vital in limiting replication in cell cycle. The prognostic role of MCMs in MM is still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0162-2DOI Listing
January 2020

RNA N-methyladenosine modification in solid tumors: new therapeutic frontiers.

Cancer Gene Ther 2020 Jan 20. Epub 2020 Jan 20.

Department of Systems Biology and The Gehr Family Center for Leukemia Research, The Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.

Epigenetic mRNA modification is an evolving field. N-methyladenosine (mA) is the most frequent internal transcriptional modification in eukaryotic messenger RNAs (mRNAs). This review will discuss the functions of the mA mRNA machinery, including its "writers" that are components of the methyltransferase complex, its "readers" and its "erasers" (specifically FTO and ALKBH5) in cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-020-0160-4DOI Listing
January 2020

Autologous CAR T-cell therapies supply chain: challenges and opportunities?

Cancer Gene Ther 2020 Jan 14. Epub 2020 Jan 14.

Dept. of Chemical Engineering, Centre for Process Systems Engineering (CPSE), Imperial College London, SW7 2AZ, Lodnon, UK.

Chimeric antigen receptor (CAR) T cells are considered a potentially disruptive cancer therapy, showing highly promising results. Their recent success and regulatory approval (both in the USA and Europe) are likely to generate a rapidly increasing demand and a need for the design of robust and scalable manufacturing and distribution models that will ensure timely and cost-effective delivery of the therapy to the patient. However, there are challenging tasks as these therapies are accompanied by a series of constraints and particularities that need to be taken into consideration in the decision-making process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0157-zDOI Listing
January 2020

Retraction Note: Blockage of miR-92a-3p with locked nucleic acid induces apoptosis and prevents cell proliferation in human acute megakaryoblastic leukemia.

Authors:
M Sharifi R Salehi

Cancer Gene Ther 2020 02;27(1-2):113

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0158-yDOI Listing
February 2020

Ectopia associated MN1 fusions and aberrant activation in myeloid neoplasms with t(12;22)(p13;q12).

Cancer Gene Ther 2020 Jan 6. Epub 2020 Jan 6.

Beijing Lu Daopei Institute of Hematology, Beijing, 100176, China.

Chromosome translocation t(12;22)(p13;q12)/MN1-ETV6 and MN1 overexpression confer a subset of adverse prognostic AML but so far lack in-depth research. We focused on the clinical course and comprehensive genetic analysis of eight cases with t(12;22)(p13;q12) and one with t(12;17;22) (p13;q21;q13) to elucidate their molecular etiology and outcomes of allogeneic hemopoietic stem cell transplantation (allo-HSCT). The total incidence of t(12;22)(p13;q12) and related translocations was 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0159-xDOI Listing
January 2020

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.

Cancer Gene Ther 2020 Jan 6. Epub 2020 Jan 6.

Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.

Oncolytic virotherapies (OV) based on human adenoviral (HAdV) vectors hold significant promise for the treatment of advanced ovarian cancers where local, intraperitoneal delivery to tumour metastases is feasible, bypassing many complexities associated with intravascular delivery. The efficacy of HAdV-C5-based OV is hampered by a lack of tumour selectivity, where the primary receptor, hCAR, is commonly downregulated during malignant transformation. Conversely, folate receptor alpha (FRα) is highly expressed on ovarian cancer cells, providing a compelling target for tumour selective delivery of virotherapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0156-0DOI Listing
January 2020

MyoD1 suppresses cell migration and invasion by inhibiting FUT4 transcription in human gastric cancer cells.

Cancer Gene Ther 2019 Dec 12. Epub 2019 Dec 12.

Department of cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, China.

Myogenic differentiation 1 (MyoD1) is a transcription factor that promotes expression of muscle-specific genes. MyoD1 is expressed at significantly lower levels in gastric cancer (GC) tissues and cells, and it induces apoptosis in GC cells. However, functions for MyoD1 in GC cell migration and gene expression have not been documented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0153-3DOI Listing
December 2019
2.416 Impact Factor

The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.

Cancer Gene Ther 2020 Feb 12;27(1-2):98-107. Epub 2019 Dec 12.

Department of Biochemistry and Molecular Biology, Medical College of Jinan University, Guangzhou, 510632, China.

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder defined by the presence of the fusion gene BCR-ABL1 in primitive hematopoietic progenitors. The myeloid leukemia factors (MLFs) were identified in the fly and human, and are involved in acute leukemia and enhancing the myeloid factor; however, the function of MLF2 in CML is poorly understood. In this study, we demonstrated that MLF2 may play an oncogenic role in CML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0152-4DOI Listing
February 2020

Challenges in assessing solid tumor responses to immunotherapy.

Cancer Gene Ther 2019 Dec 11. Epub 2019 Dec 11.

Department of Surgery, Roger Williams Medical Center, Providence, RI, USA.

With the advent of immunotherapy as an integral component of multidisciplinary solid tumor treatment, we are confronted by an unfamiliar and novel pattern of radiographic responses to treatment. Enlargement of tumors or even new lesions may not represent progression, but rather reflect what will ultimately evolve into a clinically beneficial response. In addition, the kinetics of radiographic changes in response to immunotherapy treatments may be distinct from what has been observed with cytotoxic chemotherapy and radiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0155-1DOI Listing
December 2019

BAG3 regulates multiple myeloma cell proliferation through FOXM1/Rb/E2F axis.

Authors:
Hua Bai Bing Chen

Cancer Gene Ther 2020 Feb 5;27(1-2):108-111. Epub 2019 Dec 5.

Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210008, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0154-2DOI Listing
February 2020
2.416 Impact Factor

Correction: A qualitative transcriptional signature for determining the grade of colorectal adenocarcinoma.

Cancer Gene Ther 2020 May;27(5):393

Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0151-5DOI Listing
May 2020
2.416 Impact Factor

MicroRNA-200 family expression analysis in metastatic clear cell renal cell carcinoma patients.

Cancer Gene Ther 2019 Nov 4. Epub 2019 Nov 4.

Institute of Biochemistry and Genetics, Ufa Federal Research Center of the Russian Academy of Sciences, Ufa, Russian Federation.

The aim of this study is to analyse the of expression levels of microRNA-200 family members in patients with metastatic clear cell renal cell carcinoma (ccRCC). Analysis of microRNA expression was performed on 23 paired DNA samples extracted from kidney tumour tissue and the surrounding normal renal parenchyma. MicroRna-200c was found to have significantly lower expression (in kidney tumour tissue compared to normal renal parenchyma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0149-zDOI Listing
November 2019
1 Read

Liposomal delivery of CRISPR/Cas9.

Authors:
Shuai Zhen Xu Li

Cancer Gene Ther 2019 Nov 2. Epub 2019 Nov 2.

Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, Shaanxi, PR China.

Liposomes are one of the most widely investigated carriers for CRISPR/Cas9 delivery. The surface properties of liposomal carriers, including the surface charge, PEGylation, and ligand modification can significantly affect the gene silencing efficiency. Three barriers of systemic CRISPR/Cas9 delivery (long blood circulation, efficient tumor penetration, and efficient cellular uptake/endosomal escape) are analyzed on liposomal carriers with different surface charges, PEGylations, and ligand modifications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0141-7DOI Listing
November 2019

Retraction Note: Enhanced suppression of tumor growth using a combination of NK4 plasmid DNA-PEG engrafted cationized dextran complex and ultrasound irradiation.

Cancer Gene Ther 2020 04;27(3-4):266

Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0148-0DOI Listing

Mechanism and therapeutic prospect of resveratrol combined with TRAIL in the treatment of renal cell carcinoma.

Cancer Gene Ther 2019 Oct 30. Epub 2019 Oct 30.

State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 200031, Shanghai, China.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to kill a wide variety of tumor cells with minimal effects on normal cell. However, renal cell carcinoma (RCC) cells 786-0 and OS-RC-2 were resistant to TRAIL. The present study examines the potential of combining polyphenolic compound resveratrol (RES) with TRAIL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0150-6DOI Listing
October 2019
1 Read

The incidence, genetic characteristics, and prognosis of leukemia with concurrent pathogenic fusion genes: a series of 25 cases from a large cohort of leukemia patients.

Cancer Gene Ther 2020 Feb 23;27(1-2):89-97. Epub 2019 Oct 23.

Divison of Pathology & Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, 065201, China.

Recurrent fusion genes (FGs) with clinical significances in leukemias are mainly mutually exclusive, and the coexistence of different FGs has been rarely reported. In this study, we retrospectively analyzed the incidence, genetic characteristics, and prognosis of leukemias with concurrent pathogenic FGs, which commonly reported in hematological malignancies in 8226 leukemia patients. A total of 25 patients with coexistence of double FGs were identified, accounting for 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41417-019-0147-1DOI Listing
February 2020
1 Read